Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Real-world data on PD-1 inhibitor therapy in metastatic melanoma.

Arheden A, Skalenius J, Bjursten S, Stierner U, Ny L, Levin M, Jespersen H.

Acta Oncol. 2019 Jul;58(7):962-966. doi: 10.1080/0284186X.2019.1620966. Epub 2019 May 31.

PMID:
31151362
2.

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.

Jespersen H, Olofsson Bagge R, Ullenhag G, Carneiro A, Helgadottir H, Ljuslinder I, Levin M, All-Eriksson C, Andersson B, Stierner U, Nilsson LM, Nilsson JA, Ny L.

BMC Cancer. 2019 May 2;19(1):415. doi: 10.1186/s12885-019-5623-3.

3.

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma.

Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA.

Cell Death Dis. 2018 Jul 24;9(8):810. doi: 10.1038/s41419-018-0865-6.

4.

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma.

Veppil Muralidharan S, Osk Einarsdottir B, Bhadury J, Lindberg MF, Wu J, Campeau E, Olofsson Bagge R, Stierner U, Ny L, Nilsson LM, Nilsson JA.

Cell Death Dis. 2017 Dec 14;8(12):e3177. doi: 10.1038/cddis.2017.557.

5.

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma.

Muralidharan SV, Einarsdottir BO, Bhadury J, Lindberg MF, Wu J, Campeau E, Bagge RO, Stierner U, Ny L, Nilsson LM, Nilsson JA.

Cell Death Dis. 2017 Aug 10;8(8):e2982. doi: 10.1038/cddis.2017.383. Erratum in: Cell Death Dis. 2017 Dec 14;8(12 ):e3177.

6.

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P.

Nat Med. 2017 Aug;23(8):929-937. doi: 10.1038/nm.4369. Epub 2017 Jul 17.

7.

[The melanoma incidence continues to rise].

Helgadottir H, Stierner U.

Lakartidningen. 2017 May 9;114. pii: ELAP. Swedish. No abstract available.

8.

Accelerated or conventional whole brain irradiation of malignant melanoma.

Hultborn R, Sand J, Kinhult S, Lundgren L, Stierner U, Turesson I, Albertsson P.

Acta Oncol. 2017 Jul;56(7):1021-1023. doi: 10.1080/0284186X.2016.1275777. Epub 2017 Jan 11. No abstract available.

PMID:
28075181
9.

Glycosaminoglycan Profiling in Patients' Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma.

Gatto F, Volpi N, Nilsson H, Nookaew I, Maruzzo M, Roma A, Johansson ME, Stierner U, Lundstam S, Basso U, Nielsen J.

Cell Rep. 2016 May 24;15(8):1822-36. doi: 10.1016/j.celrep.2016.04.056. Epub 2016 May 12.

10.

Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).

Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G; SWENOTECA.

Ann Oncol. 2016 Jul;27(7):1299-304. doi: 10.1093/annonc/mdw164. Epub 2016 Apr 6.

11.

Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts.

Bhadury J, Einarsdottir BO, Podraza A, Bagge RO, Stierner U, Ny L, Dávila López M, Nilsson JA.

Oncotarget. 2016 Apr 26;7(17):23801-11. doi: 10.18632/oncotarget.8181.

12.

Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Olofsson Bagge R, Ny L, All-Ericsson C, Sternby Eilard M, Rizell M, Cahlin C, Stierner U, Lönn U, Hansson J, Ljuslinder I, Lundgren L, Ullenhag G, Kiilgaard JF, Nilsson J, Lindnér P.

Trials. 2015 Aug 6;16:334. doi: 10.1186/s13063-015-0809-8. No abstract available.

13.

MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.

Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C, Hertzman Johansson C, Lindén D, Johansson H, Frostvik Stolt M, Walker C, Snowden H, Newton-Bishop J, Hansson J, Egyházi Brage S.

Int J Cancer. 2015 Jun 15;136(12):2844-53. doi: 10.1002/ijc.29332. Epub 2014 Nov 24.

14.

Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men.

Lyth J, Eriksson H, Hansson J, Ingvar C, Jansson M, Lapins J, Månsson-Brahme E, Naredi P, Stierner U, Ullenhag G, Carstensen J, Lindholm C.

Br J Dermatol. 2015 Mar;172(3):700-6. doi: 10.1111/bjd.13483. Epub 2015 Feb 5.

15.

Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.

Vihinen P, Tervahartiala T, Sorsa T, Hansson J, Bastholt L, Aamdal S, Stierner U, Pyrhönen S, Syrjänen K, Lundin J, Hernberg M.

Cancer Immunol Immunother. 2015 Feb;64(2):173-80. doi: 10.1007/s00262-014-1620-1. Epub 2014 Oct 16.

PMID:
25319807
16.

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.

Einarsdottir BO, Bagge RO, Bhadury J, Jespersen H, Mattsson J, Nilsson LM, Truvé K, López MD, Naredi P, Nilsson O, Stierner U, Ny L, Nilsson JA.

Oncotarget. 2014 Oct 30;5(20):9609-18.

17.

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.

Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Cavallin-Ståhl E, Stierner U, Wahlquist R, Wall N, Cohn-Cedermark G; SWENOTECA.

Ann Oncol. 2014 Nov;25(11):2167-72. doi: 10.1093/annonc/mdu375. Epub 2014 Aug 11.

18.

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Olofsson R, Ny L, Eilard MS, Rizell M, Cahlin C, Stierner U, Lönn U, Hansson J, Ljuslinder I, Lundgren L, Ullenhag G, Kiilgaard JF, Nilsson J, Lindnér P.

Trials. 2014 Aug 9;15:317. doi: 10.1186/1745-6215-15-317. Erratum in: Trials. 2015;16:334. All-Ericsson, Charlotta [Added].

19.

Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden.

Eriksson H, Lyth J, Månsson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, Naredi P, Stierner U, Carstensen J, Hansson J.

J Clin Oncol. 2014 May 1;32(13):1356-64. doi: 10.1200/JCO.2013.52.7564. Epub 2014 Mar 31. Erratum in: J Clin Oncol. 2014 Dec 10;32(35):4025.

PMID:
24687828
20.

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.

Brandberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J; Nordic Melanoma Cooperative Group.

Acta Oncol. 2013 Aug;52(6):1086-93. doi: 10.3109/0284186X.2013.789140. Epub 2013 Apr 28.

PMID:
23621752
21.

Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.

Eriksson H, Lyth J, Månsson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, Naredi P, Stierner U, Wagenius G, Carstensen J, Hansson J.

Eur J Cancer. 2013 Aug;49(12):2705-16. doi: 10.1016/j.ejca.2013.03.013. Epub 2013 Apr 11.

PMID:
23583439
22.

Psychological needs when diagnosed with testicular cancer: findings from a population-based study with long-term follow-up.

Skoogh J, Steineck G, Johansson B, Wilderäng U, Stierner U; SWENOTECA.

BJU Int. 2013 Jun;111(8):1287-93. doi: 10.1111/j.1464-410X.2012.11696.x. Epub 2013 Mar 7.

23.

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.

Ambring A, Björholt I, Lesén E, Stierner U, Odén A.

Med Oncol. 2013 Mar;30(1):331. doi: 10.1007/s12032-012-0331-8. Epub 2012 Dec 18.

24.

Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register.

Lyth J, Hansson J, Ingvar C, Månsson-Brahme E, Naredi P, Stierner U, Wagenius G, Lindholm C; Swedish Melanoma Study Group.

Br J Dermatol. 2013 Apr;168(4):779-86. doi: 10.1111/bjd.12095. Epub 2013 Jan 18.

25.

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b.

Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J.

Eur J Cancer. 2012 Sep;48(13):2012-9. doi: 10.1016/j.ejca.2011.11.019. Epub 2011 Dec 22.

PMID:
22196968
26.

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).

Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Ståhl E, Cohn-Cedermark G.

Acta Oncol. 2012 Feb;51(2):168-76. doi: 10.3109/0284186X.2011.641507. Epub 2011 Dec 19.

PMID:
22175254
27.

Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish population-based study 3-26 years after treatment.

Skoogh J, Steineck G, Stierner U, Cavallin-Ståhl E, Wilderäng U, Wallin A, Gatz M, Johansson B; Swenoteca.

Acta Oncol. 2012 Feb;51(2):185-97. doi: 10.3109/0284186X.2011.602113. Epub 2011 Aug 18.

PMID:
21851186
28.

Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.

Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Ståhl O, Klepp O, Bremnes RM, Cohn-Cedermark G, Langberg CW, Laurell A, Solberg A, Stierner U, Wahlqvist R, Wijkström H, Anderson H, Cavallin-Ståhl E.

J Clin Oncol. 2011 May 20;29(15):2032-9. doi: 10.1200/JCO.2010.29.1278. Epub 2011 Apr 11.

PMID:
21482994
29.

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group.

Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20.

PMID:
21256809
30.

Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.

Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G.

J Clin Oncol. 2011 Feb 20;29(6):719-25. doi: 10.1200/JCO.2010.30.1044. Epub 2011 Jan 4.

PMID:
21205748
31.

Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors.

Skoogh J, Steineck G, Cavallin-Ståhl E, Wilderäng U, Håkansson UK, Johansson B, Stierner U; SWENOTECA.

Int J Androl. 2011 Apr;34(2):183-92. doi: 10.1111/j.1365-2605.2010.01073.x.

PMID:
20550599
32.

Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.

Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, Klepp O.

Ann Oncol. 2010 Sep;21(9):1858-63. doi: 10.1093/annonc/mdq026. Epub 2010 Feb 8.

33.

Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.

Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U.

Nucl Med Commun. 2009 Jul;30(7):519-24.

PMID:
19522059
34.

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group.

J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. doi: 10.1093/jnci/djp132. Epub 2009 Jun 9.

PMID:
19509353
35.

Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrøm H, Klepp O.

J Clin Oncol. 2009 May 1;27(13):2122-8. doi: 10.1200/JCO.2008.18.8953. Epub 2009 Mar 23. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3263. J Clin Oncol. 2010 Mar 10;28(8):1438. Dosage error in article text.

PMID:
19307506
36.

Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b.

Lyrdal D, Stierner U, Lundstam S.

Acta Oncol. 2009;48(6):901-8. doi: 10.1080/02841860902795257.

PMID:
19274498
37.

The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma.

Hernberg M, Mattila PS, Rissanen M, Hansson J, Aamdal S, Bastholt L, von der Maase H, Schmidt H, Stierner U, Tarkkanen J.

J Immunother. 2007 Oct;30(7):773-9.

PMID:
17893569
38.

Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.

Lindholm C, Andersson R, Dufmats M, Hansson J, Ingvar C, Möller T, Sjödin H, Stierner U, Wagenius G; Swedish Melanoma Study Group.

Cancer. 2004 Nov 1;101(9):2067-78.

39.

[GIST--a significantly more common tumor than earlier apprehended. New discoveries on the pathogenesis of GIST yielded new medical treatment].

Nilsson B, Andersson J, Meis-Kindblom J, Kindblom LG, Engström K, Stierner U, Bümming P, Ahlman H.

Lakartidningen. 2003 Mar 13;100(11):930-4, 936-8. Review. Swedish. No abstract available.

PMID:
15148719
40.

O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.

Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J.

Br J Cancer. 2003 Oct 20;89(8):1517-23.

41.

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.

Bümming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, Wängberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B.

Br J Cancer. 2003 Aug 4;89(3):460-4.

42.

Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.

Mattsson J, Uzunel M, Brune M, Hentschke P, Barkholt L, Stierner U, Aschan J, Ringdén O.

Br J Haematol. 2001 Dec;115(4):935-44.

PMID:
11843830
43.

Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families.

Hashemi J, Bendahl PO, Sandberg T, Platz A, Linder S, Stierner U, Olsson H, Ingvar C, Hansson J, Borg A.

Genes Chromosomes Cancer. 2001 Jun;31(2):107-16.

PMID:
11319798
44.

CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.

Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J.

Cancer Res. 2000 Dec 15;60(24):6864-7.

45.

Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines.

Hanson C, Köpf I, Weijdegård B, Weimarck A, Stierner U.

Melanoma Res. 1999 Oct;9(5):451-6.

PMID:
10596911
46.

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.

Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, Malmström P, Andersson R, Karlsson M, Willman K, Wist E, Bjelkengren G, Westberg R.

Eur J Cancer. 1998 Aug;34(9):1368-74.

PMID:
9849419
47.

Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer.

Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J, Nilsson S, Daehlin L, Tørnblom M, Småland R, Starkhammar H, Abramsson L, Wist E, Raabe N, Edekling T, Cavallin-Ståhl E.

Eur J Cancer. 1997 Jun;33(7):1038-44.

PMID:
9376184
48.

Action of interferon alpha and beta on four human melanoma cell lines in vitro.

Köpf J, Hanson C, Delle U, Weimarck A, Stierner U.

Anticancer Res. 1996 Mar-Apr;16(2):791-798.

PMID:
8687130
49.

Characterization of four melanoma cell lines with electron microscopy, immunocytochemistry, cytogenetics, flow cytometry, and southern analysis.

Köpf I, Stierner U, Islam Q, Delle U, Kindblom LG, Martinsson T.

Cancer Genet Cytogenet. 1992 Sep;62(2):111-23.

PMID:
1394095
50.

Association of ploidy and cell proliferation, Dukes' classification, and histopathological differentiation in adenocarcinomas of colon and rectum.

Wahlström B, Branehög I, Stierner U, Sunzel H, Holmberg E.

Eur J Surg. 1992 Apr;158(4):237-42; discussion 242-3.

PMID:
1352139

Supplemental Content

Loading ...
Support Center